> ## Content Index > Fetch the complete content index at: https://www.whiteroseintelligence.com/llms.txt > Use this file to discover other available public pages before exploring further. # 2019 novel Coronavirus Global research and innovation forum - URL: https://www.whiteroseintelligence.com/2019-novel-coronavirus-global-research-and-innovation-forum/ - Published: 2026-07-04T16:27:00.000Z - Updated: 2026-07-04T16:29:14.000Z - Author: Liam Sturgess - Tags: Profiles, #docs, Event, Switzerland, Government, Academia, Healthcare, COVID-19, Regulatory, #toc **2019 novel Coronavirus Global research and innovation forum: towards a research roadmap** was a private conference hosted by the [World Health Organization](https://www.whiteroseintelligence.com/World-Health-Organization)'s R&D Blueprint and the [Global Research Collaboration for Infectious Disease Preparedness](https://www.whiteroseintelligence.com/Global-Research-Collaboration-for-Infectious-Disease-Preparedness) (GloPID-R). The event took place in Geneva, Switzerland on February 11-12, 2020.[\[1\]](#fn1) ## Participants and agenda **Session 1: Setting the Scene** | Name | Affiliation | Topic(s) | | -------------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------ | | Tedros Adhanom Ghebreyesus | [World Health Organization](https://www.whiteroseintelligence.com/World-Health-Organization) | Opening Remarks | | Yazdan Yazdanpanah | [Global Research Collaboration for Infectious Disease Preparedness](https://www.whiteroseintelligence.com/Global-Research-Collaboration-for-Infectious-Disease-Preparedness) (GloPID-R) | Objectives of the meeting | | Michael Ryan | [World Health Organization](https://www.whiteroseintelligence.com/World-Health-Organization) | Overview of the outbreak situation and control measures being implemented | | Representative from China | \- | Epidemiological situation and current research efforts in China | | R&D Blueprint co-leads | R&D Blueprint | Overview of WHO R&D Blueprint efforts | | Isabella Eckerle | Centre for Emerging Viral Diseases | Virus: natural history, transmission and diagnostics | | Christian Drosten | German Centre for Infection Research (DZIF) | Virus: natural history, transmission and diagnostics | | Sophie von Dobschuetz | Food and Agriculture Organization (FAO) | Animal and environmental research on the virus origin, and management measures at the human-animal interface | | Peter Daszak | EcoHealth Alliance | Animal and environmental research on the virus origin, and management measures at the human-animal interface | | Farida Al Hosani | Abu Dhabi Public Health Center | Animal and environmental research on the virus origin, and management measures at the human-animal interface | | Gabriel Leung | Li Ka Shing Faculty of Medicine | Epidemiological studies | | Yae-Jean Kim | Sungkyunkwan University | Clinical characterization and management | | Robert Fowler | Sunnybrook Research Institute, [Dalla Lana School of Public Health](https://www.whiteroseintelligence.com/Dalla-Lana-School-of-Public-Health) | Clinical characterization and management | | Anna Levin | Hospital das Clínicas, Brazilian Health Regulatory Agency, São Paulo State Health Department | Infection prevention and control, including health care workers’ protection | | John Conly | [AHS COVID-19 Scientific Advisory Group](https://www.whiteroseintelligence.com/AHS-COVID-19-Scientific-Advisory-Group), UNITY Studies | Infection prevention and control, including health care workers’ protection | | Marco Cavaleri | [European Medicines Agency](https://www.whiteroseintelligence.com/European-Medicines-Agency) (EMA) | Candidate therapeutics R&D | | Ana Laura Salvati | Italian Medicines Agency (AIFA) | Candidate therapeutics R&D | | Anuradha Poonepalli | Health Sciences Authority (HSA) | Candidate vaccines R&D | | Philip Krause | [Food and Drug Administration](https://www.whiteroseintelligence.com/Food-and-Drug-Administration) (FDA) | Candidate vaccines R&D | | Beatriz da Costa Thome | Federal University of São Paulo | Ethical considerations for research | | Ross Upshur | [Dalla Lana School of Public Health](https://www.whiteroseintelligence.com/Dalla-Lana-School-of-Public-Health), Ontario COVID-19 Bioethics Table | Ethical considerations for research | | Nina Gobat | R&D Blueprint, Platform for European Preparedness Against (Re-)emerging Epidemics (PREPARE), European Clinical Research Alliance for Infectious Diseases (ECRAID) | Integrating social sciences in the outbreak response | | Emily Chan | Government of Hong Kong, Chinese University of Hong Kong | Integrating social sciences in the outbreak response | **Session 2: Defining Knowledge Gaps, Research Priorities and a Governance Framework** | Name | Affiliation | Topic(s) | | ---------------------- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------ | | Sophie van de Werf | Pasteur Institute | Virus: natural history and transmission and diagnostics | | Isabella Eckerle | Centre for Emerging Viral Diseases | Virus: natural history and transmission and diagnostics | | Sophie von Dobschuetz | \- | Animal and environmental research on the virus origin, and management measures at the human-animal interface | | William Karesh | EcoHealth Alliance | Animal and environmental research on the virus origin, and management measures at the human-animal interface | | Farida Al Hosani | Abu Dhabi Public Health Center | Epidemiological studies | | Gabriel Leung | Li Ka Shing Faculty of Medicine | Epidemiological studies | | Yae-Jean Kim | Sungkyunkwan University | Clinical characterization and management | | John Marshall | Unity Health Toronto | Clinical characterization and management | | Srinivas Moorthy | \- | Clinical characterization and management | | Anna Levin | Hospital das Clínicas, Brazilian Health Regulatory Agency, São Paulo State Health Department | Infection prevention and control, including health care workers’ protection | | Andreas Voss | International Society of Antimicrobial Chemotherapy (ISAC) | Infection prevention and control, including health care workers’ protection | | Ana Laura Salvati | Italian Medicines Agency (AIFA) | Candidate therapeutics R&D | | Marco Cavaleri | [European Medicines Agency](https://www.whiteroseintelligence.com/European-Medicines-Agency) (EMA) | Candidate therapeutics R&D | | Anuradha Poonepalli | Health Sciences Authority (HSA) | Candidate vaccines R&D | | Philip Krause | [Food and Drug Administration](https://www.whiteroseintelligence.com/Food-and-Drug-Administration) (FDA) | Candidate vaccines R&D | | Beatriz da Costa Thome | Federal University of São Paulo | Ethical considerations for research | | Ross Upshur | [Dalla Lana School of Public Health](https://www.whiteroseintelligence.com/Dalla-Lana-School-of-Public-Health), Ontario COVID-19 Bioethics Table | Ethical considerations for research | | Lina Moses | Tulane School of Public Health and Tropical Medicine | Social sciences in the outbreak response | | Emily Chan | Government of Hong Kong, Chinese University of Hong Kong | Social sciences in the outbreak response | | Jane Ellison | [World Health Organization](https://www.whiteroseintelligence.com/World-Health-Organization) | Funders coordination and perspectives | | Yazdan Yazdanpanah | [Global Research Collaboration for Infectious Disease Preparedness](https://www.whiteroseintelligence.com/Global-Research-Collaboration-for-Infectious-Disease-Preparedness) (GloPID-R) | Funders coordination and perspectives | **Session 3: Defining Key Priorities and Overall Objectives of the Global Research Roadmap** | Name | Affiliation | Topic(s) | | ------------------- | -------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------ | | Nísia Trindade Lima | Brazil Ministry of Health, Lancet COVID-19 Commission | Plenary debate on the implications of the outcomes of the thematic areas | | Chikwe Ihekweazu | [World Health Organization](https://www.whiteroseintelligence.com/World-Health-Organization) | Plenary debate on the implications of the outcomes of the thematic areas | **Session 4: Optimizing Funding Efforts** | Name | Affiliation | Topic(s) | | ------------------ | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | ------------------------ | | Yazdan Yazdanpanah | [Global Research Collaboration for Infectious Disease Preparedness](https://www.whiteroseintelligence.com/Global-Research-Collaboration-for-Infectious-Disease-Preparedness) (GloPID-R) | Funders discussion panel | | Jane Ellison | [World Health Organization](https://www.whiteroseintelligence.com/World-Health-Organization) | Funders discussion panel | **Session 5: Conclusions and Next Steps** | Name | Affiliation | Topic(s) | | ------------------- | -------------------------------------------------------------------------------------------- | ---------------------------------------------------------- | | Jeremy Farrar | Wellcome Trust | Taking stock of deliberations and report back to Dr Tedros | | Marie-Paule Kieny | Drugs for Neglected Diseases Initiative (DNDi) | Taking stock of deliberations and report back to Dr Tedros | | Nísia Trindade Lima | Brazil Ministry of Health, Lancet COVID-19 Commission | Taking stock of deliberations and report back to Dr Tedros | | Chikwe Ihekweazu | [World Health Organization](https://www.whiteroseintelligence.com/World-Health-Organization) | Taking stock of deliberations and report back to Dr Tedros | | Soumya Swaminathan | [World Health Organization](https://www.whiteroseintelligence.com/World-Health-Organization) | Next steps: Summary by the WHO Secretariat | ## External links - [Campfire Wiki](https://www.campfire.wiki/doku.php?id=2019%5Fnovel%5Fcoronavirus%5Fglobal%5Fresearch%5Fand%5Finnovation%5Fforum%5Ftowards%5Fa%5Fresearch%5Froadmap) --- 1. *2019 novel Coronavirus Global research and innovation forum: towards a research roadmap AGENDA.* (2020). GLOPID-R. [↩︎](#fnref1)